Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.7.1 (
methylenetetrahydrofolate reductase
)
2,116
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Malabsorptive bariatric surgery is rapidly becoming a major cause of
copper
deficiency given the increasing prevalence of these procedures for morbid obesity. Acquired
copper
deficiency can present with clinically significant hematologic and neurological manifestations. Although hematologic manifestations of
copper
deficiency are rapidly reversible, significant neurological improvement after
copper
supplementation therapy is unusual and many patients remain debilitated and may only experience, at best, stabilization of the neurological manifestations. Here we present a case of an undiagnosed
copper
deficiency several years after bariatric gastric bypass surgery, in a patient who concomitantly used zinc-containing denture cream for several years, associated with anemia, neutropenia, myelopathy, respiratory failure, and bilateral optic neuropathy, which caused major vision loss. This patient was also a heterozygote carrier of the
5,10-methylenetetrahydrofolate reductase
A1298C gene polymorphism, which may affect
copper
metabolism. Intravenous
copper
repletion resulted in rapid correction of hematologic indices. However, neurological manifestations, including vision loss responded only modestly to
copper
supplementation, despite achieving normal blood
copper
concentrations. Clinicians should consider
copper
deficiency in patients at risk, as in this case, as a delayed diagnosis can lead to irreversible disability due to neurological manifestations.
...
PMID:Optic neuropathy, myelopathy, anemia, and neutropenia caused by acquired copper deficiency after gastric bypass surgery. 2458 48
Wilson disease (WD) is characterized by remarkable variety in its phenotypic presentation. Patients with WD can present with hepatic, neurologic, and psychiatric symptoms combined in different and unpredictable ways. Importantly, no convincing phenotype-genotype correlation has ever been identified, opening the possibility that other genes, aside from ATPase
copper
-transporting beta (ATP7B), are involved in the pathogenesis of this condition. In addition, modifier genes, or genes that can affect the expression of other genes, may be involved. Clinical and basic science data indicate that environmental and dietary factors can potentially modify gene expression in WD and, consequently, its clinical presentation and course. In particular, previously studied genes include
copper
metabolism domain-containing 1 (COMMD1), antioxidant 1
copper
chaperone (ATOX1), X-linked inhibitor of apoptosis (XIAP), apolipoprotein E (APOE), hemochromatosis (HFE), and
5,10-methylenetetrahydrofolate reductase
(
MTHFR
). Dietary factors include iron and methyl group donors which could affect methionine metabolism and epigenetic mechanisms of gene expression regulation. Most of the work conducted in this field is in its initial stages but it has the potential to change the diagnosis and treatment of WD.
...
PMID:Genetic and environmental modifiers of Wilson disease. 2843 8